Flex Biomedical, Inc. develops and commercializes innovative products for the treatment and diagnosis of orthopedic injuries and diseases. Flex Biomedical's lead product is a synthetic polymer, the Flex Polymer™, designed to treat osteoarthritis, an incurable joint disease that affects millions around the world.

Download the full EXECUTIVE SUMMARY in PDF format.

27 million people have Osteoarthritis (OA) in the US with direct annual cost of $70 billion.